PARIS and SAN FRANCISCO, June 21, 2017 18: 00 SpineGuard (FR0011464452 ALSGD), an innovative company that designs, develops and markets single-use medical devices for the purpose of securing the back surgery, announced today the signing of an exclusive distribution agreement with XinRong Medical for the PediGuard® in China, Hong Kong and Macau.
Download the free guide
Boost your gains
Second in the world after the United States, the chinese market for spinal surgery is estimated at approximately USD 1 billion by 2019 1. Its growth is driven by the aging of the population, the increase in the number of patients with pathologies of vertebral and improving access to care. “We are delighted with this agreement with XinRong, which has all the advantages to succeed in the marketing of PediGuard® in China, a market to trèsfort potential. The number of surgeries in spine fusion continues to grow rapidly across the country, generating a need for ever-more important in securing the establishment of the pedicle screw. Since its approval by the CFDA, many orthopaedic surgeons and neurosurgeons chinese have expressed a strong interest for the PediGuard®.
We are delighted that they can use it very soon and integrate it into their surgical practice, ” said Pierre Jérôme, ceo and co-founder of SpineGuard. “XinRong Medical is very pleased to be partnering with SpineGuard, holder of PediGuard® technology and DSG®. The PediGuard® is unique, and we are particularly excited at the idea of being able to market in China one of the surgical devices to be the most innovative. This advanced technology significantly reduces radiation exposure to teams operative and patient, while allowing the surgeons to make locations more accurate. Simplicity, efficiency, accuracy and security of the surgical operation are of clinical benefits that we aim to deliver to surgeons for the benefit of patients in China, ” adds Christine Zhang, Director General, XinRong Medical.
Next press release financial : turnover for the first half of 2017 : July 6, 2017
Founded in 2009 by Pierre Jérôme and Stéphane Bette, which is based in Paris and San Francisco, SpineGuard is an innovative company that designs, develops and markets single-use medical devices intended to secure and simplify back surgery. The objective of SpineGuard is to establish its technology in the digital DSG® (Dynamic Surgical Guidance, surgical guidance in real-time as the standard of care in the world. The PediGuard®, the first device designed from the technology DSG® and co-invented by Maurice Bourlion, Dr Ciaran Bolger and Alain Vanquaethem, allows the orthopaedic surgeons and neurosurgeons to perform a drilling, the femur with an accuracy that is unmatched. Thanks to the sensor located at its tip and the embedded electronics in its handle, the PediGuard real-time measurement and transcribed in the form of an audible signal and light to any change of electrical conductivity of the tissue encountered. More than 50,000 surgeries have been performed with devices equipped with technology DSG® across the world. Numerous clinical studies published in medical and scientific journals of reference have established the reliability and accuracy of PediGuard in the field of installation of screws vertebral for the benefit of patients, surgeons, hospital staff and health systems. SpineGuard continues to expand the scope of application of its platform technology DSG® through the establishment of strategic partnerships with innovative companies in the medical industry and the development of instruments and intelligent implants. The company is certified “innovative company” by Bpifrance since 2009.
More information on www.spineguard.fr
1 iData Research
About XinRong Medical
XinRong Medical is a leading chinese medical technology with the ambition to improve patient access to better treatments, and to provide surgeons the most advanced. XinRong Medical offers innovative devices for orthopedics, neurosurgery, reconstructive surgery and approaches that are minimally invasive. Established in 2000 in Jiangsu province in China, XinRong Medical is one of the first companies in China to have received the approval of the CFDA for the manufacture of orthopedic implants. In 2014, the company received a strategic investment from The Blackstone Group (NYSE: BX). More information about XinRong Medical on www.XRBest.Com, by phone at +86-512-58100828 and by electronic mail to the address : email@example.com.
Download the free guide
Boost your gains